Zoetis Inc. (ZTS)
Salud / Farmacéutica
The world's leading animal health company trades at 12× following a guidance cut that sent the stock down 52% from its high. The business maintains a wide moat—a brand that survives patent expiration, direct access to veterinarian prescribers, and a return on capital of 28%—and the projection path already incorporates the reduced guidance, not the prior trajectory. Very undervalued: estimated total return of +19% annually.
- Price
- $77.06
- Intrinsic value (5y, base)
- $166
- Total annual return (5y)
- 19.1%
- Status (nominal)
- Very undervalued
- Margin of safety
- +47%
The essentials
- Largest animal health company by revenue: approximately 300 product lines across eight species, direct sales in around 45 countries and presence in more than 100.
- The moat extends beyond the patent: the company's own 10-K declares that brand loyalty sustains sales after loss of exclusivity, a phenomenon that does not occur in human health, and no large-scale global generic competitor exists.
- Return on invested capital of 28% versus the 10% bar, based on real invested capital of US$10.337 billion from the March 2026 balance sheet.
- The projection path starts from the 8-K guidance of May 7, 2026 (revenues US$9.68-9.96 billion, adjusted earnings per share US$6.85-7.00), not from the 10-K trajectory.
Intrinsic value — two valuation methods
Total return at 5 years: 19.2%/year = 16.6% appreciation + 2.6% dividend. The target price ($166) is ex-dividend; the $13 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $146 · Multiples $145) exceeds the market price ($77).
Pillars of the analysis
The verdict — today vs 5 years
Today — with margin of safety: at $77 trades ~46.8% below its value discounted to today (~$145) — the wide discount we require (≥38%, equivalent to a ~15% annual return); the risk is covered by the margin, not the rate.
At 5 years — Muy infravalorado: the target price ($166) plus dividends yield above the required average return (10%) — the business compounds.
The bridge: the return at 5 years comfortably exceeds the risk-free rate (4.5%) — and the discount reaches the required margin of safety.
Thesis
The business
Zoetis is the leader of an industry without a large-scale global generic, with a brand the company's own filing declares capable of retaining sales after patent expiration and a direct commercial relationship with the prescribing veterinarian. The return on real invested capital from the balance sheet is 27.5%, well above the 10% bar, and the business converts that profitability to cash: the operating flow for the trailing period was US$2.790 billion against capex of US$553 million.
The valuation
It is valued on P/E of adjusted earnings, the metric for the pharmaceutical archetype, which is already after interest and thus delivers the value of equity without a debt bridge. Year 1 starts from the 8-K guidance of May 7, 2026 and not from the 10-K trajectory, and the 17× exit multiple sits in the midrange of the 14× to 22× band for the archetype. The five-year price target is $166 against $77 of current trading.
The margin of safety
There is a margin of safety: the market's perception is meaningfully worse than reality. The maximum price to pay today to demand 15% annually is +16%. The estimated total return is +19% annually and breaks down into +17% of appreciation and +3% of dividends, with a current yield of 2.8%. The verdict is Very undervalued and rests on adjusted earnings growth, not multiple expansion: the base case exits at 17× against the 12× of entry.
What to monitor
The test that decides the thesis is whether the 11% contraction in the companion animal segment in the United States is a one-quarter adjustment or the start of sustained price compression. The two concrete indicators: the contribution of price to operating growth, which was approximately 4 points in 2025, and the trajectory of the Simparica and Apoquel franchises, which together are 28% of revenue and face exclusivity expirations within the forecast window.
Educational / informational. Does not constitute investment advice.